Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine

Table 3 Pairwise comparisons of the estimated marginal means based on the efficacy endpoint (Composite DSST) in the intent-to-treat population

(I) Treatment Allocation x Week	(J) Treatment Allocation x Week	Mean Difference (I-J)	Standard Error	95% Confidence Interval
(I) Treatment Allocation x Week	(J) Treatment Allocation x Week	Mean Difference (I-J)	Standard Error	Lower	Upper	P-value
Adjusted Model †
Treatment Allocation (Placebo) x Week 8	Treatment Allocation (Placebo) x Week 0	0.289	0.171	-0.046	0.624	0.091
Treatment Allocation (Vortioxetine) x Week 8	Treatment Allocation (Vortioxetine) x Week 0	1.933^a**	0.594	0.769	3.097	0.001
Treatment Allocation (Vortioxetine) x Week 8	Treatment Allocation (Placebo) x Week 0	0.910^a**	0.307	0.307	1.512	0.003
Treatment Allocation (Vortioxetine) x Week 8	Treatment Allocation (Placebo) x Week 8	0.621^a*	0.313	0.008	1.234	0.047

Pairwise comparisons of the estimated marginal means based on the original scale of the dependent variable (DSST total score), with moderation by inflammation, metabolic dysfunction and BMI.
a. The mean difference is significant at the 0.05 level
† Adjusted for sociodemographics, clinical characteristics, anthropometric measures and confirmed COVID-19 diagnosis
*p < 0.05, **p < 0.01

ISSN: 1744-859X